Alkem Laboratories Limited has disclosed receiving a GST demand order from Kerala tax authorities, marking a regulatory development that the pharmaceutical company plans to contest through legal channels.

GST Demand Details

The company received an order from the State Tax Officer, Taxpayer Services Circle, Thrippunithura Ernakulam Kerala, on December 24, 2025. The demand pertains to FY2021-22 operations under the company's Kerala GSTIN.

The demand has been raised under applicable provisions of the IGST Act, 2017, with the primary allegation being excess availment of Input Tax Credit (ITC).

Company's Response and Legal Action

Alkem Laboratories has clearly stated its disagreement with the demand order and confirmed its intention to contest the same. The company is in the process of taking appropriate actions, including filing an appeal against the order.

The pharmaceutical company emphasized that it does not agree with the allegations made in the demand order, setting the stage for a legal challenge to the tax authorities' assessment.

Financial Impact Assessment

According to the company's disclosure, there is no material impact expected on its financial, operational, or other activities. The relatively modest amount of ₹3.82 lakh appears manageable for the large-cap pharmaceutical company.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company noted that the order was received on December 24, 2025, and the intimation was submitted on the first working day following receipt of the order, demonstrating compliance with regulatory timelines.

The information has been made available on the company's website at www.alkemlabs.com , ensuring transparency for stakeholders and investors.

Alkem Laboratories has announced a key senior management change with the resignation of Mr. Vijay Shetty, Senior Vice President-Global Distribution Supply Chain, effective December 12, 2025. The pharmaceutical company made this disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations.

Resignation Details

The company informed stock exchanges that Mr. Shetty has tendered his resignation to pursue better opportunities outside the organization. His departure represents a significant change in the senior management team responsible for global distribution and supply chain operations.

Timeline and Process

According to internal communications, Mr. Shetty initially submitted his resignation on October 13, 2025. However, after discussions with the company's CEO and management team, his last working day was extended to December 12, 2025. This timeline suggests a structured transition process to ensure continuity in the company's global distribution and supply chain functions.

Regulatory Compliance

Alkem Laboratories has fulfilled its disclosure obligations under SEBI regulations by notifying both the National Stock Exchange of India Limited and BSE Limited about this senior management change. The company provided all required details as per Regulation 30 read with Schedule III, Part A, Para A(7) of the SEBI LODR Regulations and the SEBI Master Circular dated November 11, 2024.

Corporate Communication

The resignation letter reveals Mr. Shetty's appreciation for the support and guidance received during his tenure. He expressed gratitude toward the management, colleagues, and team members for their cooperation throughout his time with the pharmaceutical company. This professional transition reflects the company's commitment to maintaining positive relationships even during leadership changes.

The disclosure has been made available on the company's official website at www.alkemlabs.com , ensuring transparency for all stakeholders. Alkem Laboratories continues to operate its global distribution and supply chain functions while managing this senior management transition.